• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Join the Alliance

The International Alliance of ALS/MND Associations encourages all organizations involved in support of people living with ALS/MND or have an interest in ALS/MND to apply for membership.

The Alliance offers three types of membership: Full, Affiliate, and Honorary. Each has its own criteria, application requirements, and fees.

Membership Criteria, Application Requirements & Fees

Full Membership

To qualify for Full Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be chartered in their own country as a non-profit national or independent organization for at least 2 years;
  • Have a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership which includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement.

Applicants for Full Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Full Membership is either an amount equal to 0.2% of total annual income of the applicant organization or £100 (Pounds Sterling), whichever is greater. At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Affiliate Membership

Affiliate Membership in the Alliance falls within four categories:

  1. Emerging Associations Affiliate: New ALS/MND Associations being established or recently chartered in own country as a non-profit organization (or status pending) by July 1st of the current membership year.
  2. Network Affiliate:
    1. Regional non-profit networks of researchers and clinicians collaborating on ALS/MND
    2. Regional non-profit patient networks providing resources and support to people living with ALS/MND
    3. Non-profit neurological alliances advocating for and supporting people with neurological conditions
  3. Education and Research Affiliate: Education or research institutes and centres dedicated to ALS/MND that operate within a non-profit entity such as a university.
  4. Fiscal Sponsorship/Hosting Arrangement Affiliate: Organizations focused on ALS/MND that are not independently chartered and operate under the legal or administrative framework of a sponsoring or host organization.

To qualify for Affiliate Membership, an organization must:

  • Serve people with ALS/MND or related disorders with a focus on patient care, advocacy and/or research;
  • Be formally established in their own country as a non-profit organization, operate within a non-profit entity, or function under the legal or administrative structure of a sponsoring/host organization;
  • Be governed directly or indirectly by a legal constitution or by-laws;
  • Be governed by a volunteer Board of Directors (however described), elected by and/or from the membership that includes people living with ALS/MND, carers, past carers, or people closely associated with the disease; and
  • Prepare an annual financial statement (where administratively relevant).

Applicants for Affiliate Membership must submit the following documents in English:

  • Cover letter stating their reasons for wanting to become a member of the Alliance
  • Proof of non-profit status in their country
  • Copy of their constitution and/or by-laws
  • List of names of the Board of Directors (however described) and Officers
  • Mission or purpose statement of the organization
  • Written financial statement of previous year’s income (only for Emerging Associations, if available, and Network Affiliates)
  • Copies of or weblinks to brochures and other materials (if not in English, then with some English translation)

The fee for Affiliate Membership is £100 (Pounds Sterling). At the discretion of the Board of Trustees, fees can be waived or reduced for members that demonstrate need and make a request in writing.

Honorary Membership

Honorary Membership is awarded at the discretion of the Alliance’s Board of Trustees to individuals who have made significant contributions to the Alliance’s mission of a world free of ALS/MND. This may include former Board Members, Patrons, Staff, or Award recipients.

 

For any questions or for further information, please contact the CEO at alliance@als-mnd.org.

The Board reviews applications quarterly. You will be notified of the decision by email.

We encourage prospective members to attend the Alliance Meeting. Observer status will be granted.

Primary Sidebar

  • Ali Var, Turkey

    Ali Var, Turkey

  • Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

    Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

  • Jason Goodman, Les Turner ALS Foundation, USA

    Jason Goodman, Les Turner ALS Foundation, USA

  • Margreth Burger-Saile, Diagnosed 2011,  ALS Schweiz,  Switzerland

    Margreth Burger-Saile, Diagnosed 2011, ALS Schweiz, Switzerland

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Liz Ogg, Diagnosed 2013 , MND Scotland, UK

    Liz Ogg, Diagnosed 2013 , MND Scotland, UK

  • Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

    Chen Yin Xue, Taiwan MND Association, Diagnosed 1995, Taiwan

  • Claudette Sturk, ALS Society of Canada

    Claudette Sturk, ALS Society of Canada
    Picture2

  • Frank "Papa" Taylor, USA

    Frank “Papa” Taylor, USA

  • Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

    Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

  • Norm MacIsaac,  ALS Society of Canada,  ALS Society of Quebec,  Diagnosed 2014

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014

  • 393647_2252248542053_984912751_n

    393647_2252248542053_984912751_n

  • Ann Nicol

    Ann Nicol

  • Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

    Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

  • Den Haag, Diagnosed 2016 , The Netherlands

    Den Haag, Diagnosed 2016 , The Netherlands

  • Brian Lovell, Diagnosed 2011 . MND Australia

    Brian Lovell, Diagnosed 2011 . MND Australia

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Jan Zuring, Diagnosed 2010 , The Netherlands

    Jan Zuring, Diagnosed 2010 , The Netherlands

  • Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Fabio Correia

    Fabio Correia

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

  • 83

    83

  • Glen Elison,  ALS Hope Foundation,  Diagnosed 2019,  USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Liam Dwyer, England

    Liam Dwyer, England

  • Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

    Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

  • Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

  • Ada Garrido Benavidez, Diagnosed 2016,  FYADENMAC, Mexico

    Ada Garrido Benavidez, Diagnosed 2016, FYADENMAC, Mexico

  • Josée Kolijn-de Man, Diagnosed 2015 , ALS Patients Connected, The Netherlands

    Josée Kolijn-de Man, Diagnosed 2015 , ALS Patients Connected, The Netherlands

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

  • Bjarne Hytjanstorp, ALS Norge, Norway

    Bjarne Hytjanstorp, ALS Norge, Norway

  • Joanne Pratt, Diagnosed 2011 , MND Australia

    Joanne Pratt, Diagnosed 2011 , MND Australia

  • Sébastien Batiot, Diagnosed 2012 , ARSLA, France

    Sébastien Batiot, Diagnosed 2012 , ARSLA, France

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • Roxana Canova, Diagnosed 2012 ,  Asociación ELA Argentina

    Roxana Canova, Diagnosed 2012 , Asociación ELA Argentina

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Ailsa Malcolm-Hutton, Diagnosed 2013,  MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013, MND Association of England, Wales and N Ireland

  • Wilfried Leusing, Diagnosed 2010 , DGM, Germany

    Wilfried Leusing, Diagnosed 2010 , DGM, Germany

  • Andrietta

    Andrietta

  • Alan Liz Ogg 29042016 000799 lo res

    Alan Liz Ogg 29042016 000799 lo res

  • Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

    Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

  • Bayley, Australia

    Bayley, Australia

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login